Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls

Brief Title

Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls

Official Title

Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls

Brief Summary

      Analysis of mucus, mucin and DNA concentration, MUC5B/5AC ratio, rheology, osmotic pressure,
      cohesion and nucleotides in sputum on 30 individual samples of good quality in healthy
      individuals and those with bronchiectasis. (60 total)
    

Detailed Description

      In this study the investigators will investigate the mucus properties in individuals with
      idiopathic bronchiectasis and healthy individuals without a history of lung disease. In order
      to understand how mucus is abnormal in disease conditions, the investigators need to
      understand the mucus biochemical and biophysical properties in healthy individuals. In this
      study the investigators will prospectively recruit patients with bronchiectasis and healthy
      individuals from the community to provide airway sputum samples. In these samples the
      investigators will measure an array of mucus properties. This will help our understanding of
      the mucus-obstructive lung diseases and facilitate the development of appropriate and
      effective disease prevention strategies.

      A key question is whether mucus is hyper-concentrated and has abnormal biophysical properties
      in individuals with mucus-obstructive lung disease. To answer this question, the
      investigators need to understand the properties of the mucus in individuals with idiopathic
      bronchiectasis and no history of lung disease. This study will allow us to collect airway
      mucus (sputum) from individuals with bronchiectasis and healthy individuals with no history
      of lung disease.
    

Study Type

Observational

Primary Outcome

Mucus concentration (% solids)

Secondary Outcome

 Biophysical properties of mucus by rheology

Condition

Bronchiectasis Adult

Study Arms / Comparison Groups

 control

Description:  healthy individuals with no history of lung disease

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Estimated Enrollment

30

Start Date

March 10, 2017

Completion Date

June 27, 2017

Primary Completion Date

June 27, 2017

Eligibility Criteria

        Participants who meet all the following criteria are eligible for the study:

          -  Written informed consent

          -  Bronchiectasis patients: Available CT of the chest that shows evidence of dilated
             airways fulfilling radiographic criteria for bronchiectasis in more than one lobe and
             chronic cough.

        Participants who meet any of the following criteria will not be eligible for the study:

          -  Healthy individuals: A history of lung disease, current asthma symptoms or medication
             use, premature birth (<37 week gestation), a history of lung disease of infancy, or
             neurological or cardiovascular illness, current smoker or a history of smoking tobacco
             products.

          -  Bronchiectasis patients: Premature birth (<37 week gestation), a history of lung
             disease of infancy, or neurological or cardiovascular illness.

          -  Younger than 18 years of age
      

Gender

All

Ages

18 Years - 99 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Richard Boucher, MD, , 

Location Countries

United States

Location Countries

United States

NCT ID

NCT03125174

Organization ID

16-3142

Responsible Party

Sponsor

Study Sponsor

University of North Carolina, Chapel Hill

Study Sponsor

Richard Boucher, MD, Study Chair, University of North Carolina, Chapel Hill

Verification Date

July 2017